One of Cambridge’s emerging gene therapy startups has raised $110 million to support the company as it heads toward in-human trials.
Generation Bio closed the Series C round this week, bringing in new investors T. Rowe Price, Farallon and Wellington Management, as well as previous backers Atlas Venture, Fidelity and others.
The Series C round brings the total money raised by Generation Bio to more than $235 million. It’s also the first financing round led by former Vertex Pharmaceuticals (Nasdaq: VRTX) Chief Financial Officer Thomas Graney, who took the same position at Generation Bio in Dec. 2018.
Generation Bio plans to use the money to push its two lead candidates — intended to treat the blood disorder hemophilia A and rare disease phenylketonuria (PKU) — into the last stages of preclinical testing.
